
A Phase 1 clinical trial led by Imperial College London has tested a novel vaccine, VLP Peanut, designed to offer long-term protection against peanut allergy. Early results suggest the vaccine is well tolerated, reduces allergic responses, and promotes immune tolerance.
Read more